心血管药物与COVID-19临床结局:随机对照试验的系统综述与荟萃分析
该研究更新了先前基于观察性研究的系统综述与荟萃分析,聚焦新发表的随机对照试验(RCT),检索2020年11月至2021年10月间超过500个数据库。共纳入24项RCT进行定性合成,21项进行定量合成,主要涉及ACEI/ARB和抗凝药。荟萃分析显示ACEI/ARB和治疗性抗凝均未影响COVID-19住院时长、疾病严重程度或死亡率,中等至高质量RCT证据提示不应停用这些心血管药物,也不应超适应证用于治疗或预防COVID-19。
要点
- ACEI/ARB不增加COVID-19住院时长、严重程度或死亡风险,不应因COVID-19停用。
- 治疗性抗凝同样不改善COVID-19住院时长、严重程度或死亡率。
- 不应启动ACEI/ARB或抗凝药来治疗或预防COVID-19,除非有已批准的其他适应证。
核心结论
- 中等至高质量RCT证据表明ACEI/ARB等心血管药物与不良COVID-19结局无关,不应停用。
- 这些心血管药物也不应超适应证用于治疗或预防COVID-19。
研究设计与样本
- 系统综述与荟萃分析,聚焦新发表的随机对照试验(RCT)。
- 纳入24项RCT进行定性合成,21项进行定量合成。
主要发现
- ACEI/ARB未影响住院时长(均数差-0.42,95%CI -1.83至0.98天,n=1183)。
- ACEI/ARB未影响COVID-19严重程度(RR 0.90,95%CI 0.71至1.15,n=1661)或死亡率(RR 0.92,95%CI 0.58至1.47,n=1646)。
- 治疗性抗凝未影响住院时长(均数差-0.29,95%CI -1.13至0.56天,n=1449)、严重程度(RR 0.86,95%CI 0.70至1.04,n=2696)或死亡率(RR 0.93,95%CI 0.77至1.13,n=5689)。
- 其他药物类别包括抗血小板药(阿司匹林,2项试验)、抗血栓药(舒洛地特,1项试验)、钙通道阻滞剂(氨氯地平,1项试验)和调脂药(阿托伐他汀,1项试验)。
临床怎么用
- 临床不应因COVID-19而停用ACEI/ARB等心血管药物。
- 不应启动ACEI/ARB或抗凝药来治疗或预防COVID-19,除非有已批准的其他适应证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To update our previously reported systematic review and meta-analysis of observational studies on cardiovascular drug exposure and COVID-19 clinical outcomes by focusing on newly published randomized controlled trials (RCTs). METHODS: More than 500 databases were searched between 1 November 2020 and 2 October 2021 to identify RCTs that were published after our baseline review. One reviewer extracted data with other reviewers verifying the extracted data for accuracy and completeness. RESULTS: After screening 22 414 records, we included 24 and 21 RCTs in the qualitative and quantitative syntheses, respectively. The most investigated drug classes were angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blocker (ARBs) and anticoagulants, investigated by 10 and 11 studies respectively. In meta-analyses, ACEI/ARBs did not affect hospitalization length (mean difference -0.42, 95% confidence interval [CI] -1.83; 0.98 d, n = 1183), COVID-19 severity (risk ratio/RR 0.90, 95% CI 0.71; 1.15, n = 1661) or mortality (risk ratio [RR] 0.92, 95% CI 0.58; 1.47, n = 1646). Therapeutic anticoagulation also had no effect (hospitalization length mean difference -0.29, 95% CI -1.13 to 0.56 d, n = 1449; severity RR 0.86, 95% CI 0.70; 1.04, n = 2696; and, mortality RR 0.93, 95% CI 0.77; 1.13, n = 5689). Other investigated drug classes were antiplatelets (aspirin, 2 trials), antithrombotics (sulodexide, 1 trial), calcium channel blockers (amlodipine, 1 trial) and lipid-modifying drugs (atorvastatin, 1 trial). CONCLUSION: Moderate- to high-certainty RCT evidence suggests that cardiovascular drugs such as ACEIs/ARBs are not associated with poor COVID-19 outcomes, and should therefore not be discontinued. These cardiovascular drugs should also not be initiated to treat or prevent COVID-19 unless they are needed for an underlying currently approved therapeutic indication.
引用
- Asiimwe IG, Pushpakom SP, Turner RM, et al. Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2022. PMID: 35322889. doi:10.1111/bcp.15331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。